Cough
Conditions
Interventions
Registered cases for 1 year from the start of the study will be allocated to the control group in which we perform diagnosis and treatment based on the guidelines. Treatment in two or more disease sta
Sponsors
Sagamihara National Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Aged 20 to 75 at the time of case registration (2) First-visit patients whose main complaint is cough (currently not in hospital with other respiratory diseases in the department) (3) Patients with cough lasting more than 3 weeks accompanying little sputum (4) Whose VAS of the cough in the last week at the visit is 5 cm or more (5) Provided informed consent to various examinations, medical questionnaires, cough diary entries of up to 10 weeks after the start of control/intervention period, drug restrictions related to diagnostic treatment and antitussive agent, and provided written consent for participation in this study
Exclusion criteria
Exclusion criteria: (1) Confirmed obvious cough improvement naturally or by treatment during the course before visit (2) Having a history of treatment as asthma including cough asthma within three years besides this episode (3) Having a history or complications of chronic respiratory/heart/kidney disease, GERD, autoimmune /inflammatory bowel disease, tonsil hypertrophy, or laryngeal disease (4) Pregnant or possibly pregnant (5) Having a history of drug irritation or severe side effects to macrolide antibiotics, PPI, ICS, H1 blocker, H2 blocker, or beta stimulant (6) Confirmed pulmonary shadow abnormality or obvious heart expansion in chest X-ray (7) With obvious airway infection symptoms (fever of 37.5 degree Celsius. or higher or purulent sputum) at the initial visit to the institution (8) Whose Brinkman Index (average number of smokers per day x total smoking years) is 400 or more (9) With the rale sound by consultation including mild rales and forced expiration. (To listen carefully to mild twisting sounds in the lower lungs and auscultation with mild wheezing (10) Using ACE inhibitors (but can enter at 2 weeks or later after discontinuation) (11) Taking orally H2 blockers, PPI, oral steroids, systemic immunosuppressants or psychotropic drugs for some underlying disease (12) Others where the attending doctor judged inappropriate to participate in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of days required to be judged as cough improved since first visit (improvement of VAS 60% or more maintained for more than 3 days) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Frequency of cases judged to have improved cough 2) Clinical diagnosis on the cause of cough 3) Adverse events | — |
Countries
Japan
Contacts
Public ContactKiyoshi Sekiya
NHO Sagamihara National Hospital Allergology
Outcome results
None listed